Calamai Martino
1. Studying the molecular basis of Alzheimer’s disease, in particular the influence of cholesterol and neuronal activity on the processing of the amyloid precursor protein.
2. Investigating the release from nanoparticles and diffusion of drugs by means of single molecule tracking within the context of nose to brain delivery of biopharmaceutics to treat Multiple Sclerosis.
3. Translating basic research methods to the clinical diagnosis of infantile metabolic neurodegenerative diseases, such as GM1 Gangliosidosis.Main experiences acquired: Advanced imaging techniques and single molecule tracking in cells.Scientific manager for INO of Funded Projects: Automated digital scanning and diagnosis of tissues using multimodal non-linear optical microscopyLate onset Lysosomal Storage Disorders (LSDs) in the differential diagnosis of neurodegenerative diseases: development of new diagnostic procedures and focus on potential pharmacological chaperones (PCs)Research Groups: Biomolecular imaging and diagnosisOthers Funded Projects in which he/she participates: OPTO-19F-LUIDICS: FLUORINATED HYBRID PHOTOPOLYMERS FOR THE FABRICATION OF ROBUST DIAGNOSTIC OPTOFLUIDIC DEVICESPublications, Research Results, now, in INO’s database are: 39 – Papers JCR/ISI Journals, are: 37 – Books or Chapters, are: 2 – Papers in Journals not indexed JCR/ISI, are: 2 – Conference proceedings, are: 1 – Abstract, are: 2Bibliometric indices are calculated USING ONLY THE INO DATABASE and the number of citations from “WEB OF SCIENCE” (of Thomson Reuters) is updated at 2024-10-13 – maximum number of citations for an article: 248 – maximum impact factor (IF) for a journal when an article is published: 19.684 – H-INDEX: 18 G-INDEX: 37 HC-INDEX (contemporary): 14 – List of TopTen papers in citations – List of TopTen journals in Impact Factor